Legal Representation
Attorney
JOHN P. MURTAUGH
USPTO Deadlines 0 active
All 4 deadline(s) have been cleared by subsequent events.
No active deadlines at this time.
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 28, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Mar 28, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jan 10, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 10, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Dec 21, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 2, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Dec 1, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Nov 30, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Nov 30, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Nov 17, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Nov 17, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Nov 17, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Nov 11, 2022 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Oct 4, 2022 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Sep 20, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Sep 20, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Sep 20, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Sep 20, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Sep 20, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sep 19, 2022 | DOCK | D | ASSIGNED TO EXAMINER |
| Dec 16, 2021 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Dec 15, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Dec 14, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 035
Assistance, advisory services and consultancy with regard to business planning; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Business consulting services; Business consulting services in the field of potential medical cures including cell and gene therapies; Business consultation in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, chemistry, manufacturing and controls, and quality assurance/quality control; Business consulting services, namely, providing assistance in development of business strategies and creative ideation; Business management consulting and advisory services; Business support services, namely, business consulting to freelancers, start-ups, existing businesses and non-profit organizations; Consultancy and advisory services in the field of business strategy; Consulting services in the field of medical product approval for commercial purposes; International business consulting services relating to USA and outside of USA product, clinical and commercial development of investigational or approved medical products; New business venture development and formation consulting services; Promoting the exchange of information and resources within the scientific research communities to achieve advances in the field of 21st century transformational science; Providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; Providing independent review of clinical trials for business purposes; Promoting technical and scientific investigation, research and experimentation in the field of scientific discovery through support of educational institutions and scientific organizations
First Use Anywhere:
Jun 30, 2017
First Use in Commerce:
Jun 30, 2017
Class 036
Financial consulting services, namely, advising others regarding intellectual property investments; Investment consultation in the fields of product, technical, regulatory, preclinical, clinical, and commercial diligence for innovative potential or investigational medical products
First Use Anywhere:
Jun 30, 2017
First Use in Commerce:
Jun 30, 2017
Class 042
Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research information in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, manufacturing/CMC and quality assurance/quality control; Providing information about medical and scientific research; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific and technological services, namely, scientific research in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Scientific research consulting in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Scientific research and development; Technological planning and consulting services in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific consulting and research services relating to foods and dietary supplements; Scientific research consulting in the field of cosmetics
First Use Anywhere:
Jun 30, 2017
First Use in Commerce:
Jun 30, 2017
Class 044
Consulting services in the field of health; Consulting services to health care providers in the field of treating life-changing or life-threatening diseases
First Use Anywhere:
Aug 31, 2017
First Use in Commerce:
Aug 31, 2017
Additional Information
Design Mark
The mark consists of the words HYBRID CONCEPTS above the word INTERNATIONAL, the letter Os being atoms or cells within a molecular or cellular design.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
035
036
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"INTERNATIONAL"